Skip to content
In Stock Nolvadex
Breast Cancer

Nolvadex

Nolvadex is taken by mouth as a tablet, with or without food, for conditions that respond to tamoxifen’s anti-oestrogen activity. It is used mainly in oncology care, where it blocks oestrogen…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Tamoxifen
Select dosage:
Select pack Package Per unit Price
$ 2.64 $ 158.42
$ 2.18 $ 237.63 $ 195.80 Save 18%
$ 1.93 $ 316.84 $ 231.40 Save 27%
$ 1.71 $ 475.26 $ 307.94 Save 35%
Free Regular Delivery $ 1.56 $ 712.89 $ 421.86 Save 41%
Best value Free Regular Delivery $ 1.48 $ 950.52 $ 534.00 Save 44%
$ 2.79 $ 167.32
$ 2.37 $ 250.98 $ 213.60 Save 15%
$ 2.20 $ 334.64 $ 263.44 Save 21%
$ 1.97 $ 501.96 $ 354.22 Save 29%
Free Regular Delivery $ 1.85 $ 752.94 $ 498.40 Save 34%
Best value Free Express Delivery $ 1.78 $ 1,003.92 $ 642.58 Save 36%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Nolvadex is taken by mouth as a tablet, with or without food, for conditions that respond to tamoxifen’s anti-oestrogen activity. It is used mainly in oncology care, where it blocks oestrogen signalling in breast tissue.

Product information

Nolvadex contains tamoxifen, a selective oestrogen receptor modulator (SERM). The tablets are supplied for oral administration. Tamoxifen is used in breast cancer treatment and prevention of recurrence when tumour growth is influenced by oestrogen signalling. Its clinical use requires an oncology treatment plan rather than self-directed hormone adjustment. The dose is decided individually, taking age, other medicines, and health conditions into account.

Ingredients

Nolvadex contains tamoxifen, a selective oestrogen receptor modulator (SERM). The tablets are supplied for oral administration. The dose is decided individually, taking age, other medicines, and health conditions into account.

Therapeutic indications

It is used mainly in oncology care, where it blocks oestrogen signalling in breast tissue.

Tamoxifen is used in breast cancer treatment and prevention of recurrence when tumour growth is influenced by oestrogen signalling.

Directions for use

Nolvadex is taken orally according to the individual regimen prescribed for the patient’s diagnosis. Treatment schedules vary between adjuvant breast cancer therapy, risk-reduction treatment, and other specialist uses. The dose is decided individually, taking age, other medicines, and health conditions into account.

  • Swallow the tablet with water.
  • Take it at the same time each day when possible.
  • It may be taken with or without food.
  • Do not double the next dose after forgetting one.
  • If a missed dose is remembered near the next scheduled dose, skip the missed tablet and return to the usual schedule.
  • Do not stop long-term treatment without a planned instruction from the prescribing team.

The Australian product information and oncology protocols determine the appropriate duration. A course can extend over years, so adherence matters even when the patient feels well. Tamoxifen is intended to reduce hormone-responsive cancer risk or recurrence; it is not a medicine whose benefit can be judged from one day’s symptoms. [3]

Use a calendar or medication reminder for long-term treatment. Marking the dose after swallowing it helps prevent the common mistake of taking a second tablet because the first dose was forgotten.

Do not crush, chew, or split a tablet unless the prescriber or dispensing pharmacist has confirmed that the specific tablet can be handled that way. Keep the medicine away from children and avoid leaving tablets in a hot car or damp bathroom.

When not to use it

Nolvadex is not suitable for everyone. It is not for you if you are pregnant or breastfeeding, unless a specialist has given specific advice. It should not be used during pregnancy because tamoxifen may harm a developing fetus. Breastfeeding is generally incompatible with treatment because tamoxifen may suppress lactation and the infant exposure risk is not acceptable.

Nolvadex may be unsuitable or require a specialist plan in the following situations:

  • Previous deep-vein thrombosis or pulmonary embolism.
  • A known clotting disorder.
  • Unexplained vaginal bleeding.
  • Significant liver disease.
  • Allergy to tamoxifen or an excipient.
  • Concurrent anticoagulant treatment requiring close monitoring.
  • Planned surgery or prolonged immobility.
  • Use of strong CYP2D6-inhibiting medicines.

Warfarin and other anticoagulants require careful review because bleeding risk and anticoagulant response may change. Rifampicin and other enzyme-inducing medicines can also alter tamoxifen exposure.

When this is not for you

Nolvadex is not for you if you are pregnant or breastfeeding, unless a specialist has given specific advice. Tell the prescribing team if you have had a blood clot, unexplained vaginal bleeding, liver disease, or an allergy to tamoxifen. You should also seek advice before treatment if you are planning surgery, expect prolonged immobility, or take antidepressants, anticoagulants, hormonal products, seizure medicines, or herbal products.

Keep a current list of every medicine and supplement, including occasional painkillers and herbal menopause products. Interaction checks are more reliable when the list includes the dose and how often each item is taken.

Unwanted effects

Tamoxifen can produce symptoms related to reduced oestrogen signalling. The most familiar physical effect is a hot flush, which may involve a sudden wave of heat, sweating, skin redness, and a faster heartbeat. Australian and international product information also describes nausea, fluid retention, vaginal discharge or bleeding, menstrual changes, fatigue, and headache among possible adverse effects.

Reaction Practical response
Hot flushes and night sweats Use light clothing, keep the bedroom cool, and record triggers such as alcohol, spicy food, or warm rooms.
Nausea or stomach discomfort Taking the tablet with food may help, although Nolvadex can be taken with or without food. Persistent vomiting needs medical review because doses may be lost.
Vaginal bleeding or discharge Report new, persistent, or post-menopausal bleeding promptly rather than waiting for the next routine appointment.

The intensity of symptoms varies. Some people notice changes during the first weeks, while others develop symptoms gradually or experience only mild discomfort. Hot flushes may continue during treatment because tamoxifen changes oestrogen receptor signalling for as long as the medicine is used. [2]

Managing Vasomotor Symptoms

Simple adjustments can reduce disruption:

  • Keep a written record of flushes, sleep disturbance, and possible triggers.
  • Choose breathable clothing that can be removed in layers.
  • Reduce exposure to overheated rooms before bedtime.
  • Discuss non-hormonal treatment options if night sweats interfere with sleep.
  • Avoid starting herbal products for menopausal symptoms without checking for interactions.

Hormone replacement therapy is not automatically suitable during tamoxifen treatment because it may introduce oestrogenic stimulation. The decision depends on the cancer diagnosis, recurrence risk, treatment plan, and specialist advice.

A small bedside fan, layered sleepwear, and a symptom diary can be more useful than trying several products at once. The diary also gives the oncology team a clearer pattern to assess.

Common tolerability problems include hot flushes, night sweats, nausea, fatigue, headache, vaginal discharge, menstrual irregularity, and mood changes. Some patients experience muscle or joint discomfort. Symptoms may be mild, while others interfere with sleep or work.

Serious reactions require prompt medical attention:

  • New calf pain or swelling.
  • Sudden chest pain, breathlessness, or coughing blood.
  • Sudden weakness, speech difficulty, or facial drooping.
  • Unusual or persistent vaginal bleeding.
  • Vision changes.
  • Yellowing of the skin or eyes.
  • Severe abdominal pain.
  • Facial swelling, wheezing, or widespread rash.

Tamoxifen is associated with venous thromboembolism and, in post-menopausal patients, an increased risk of endometrial changes and endometrial cancer. The absolute risk depends on age, treatment duration, personal history, and other risk factors. Unusual vaginal bleeding needs assessment.

A further detail matters for surgery and prolonged immobility. The oncology team may review tamoxifen before major surgery or a long period of bed rest because clot risk can rise in those settings. Do not make that decision alone.

Mechanism of action

At the cellular level, tamoxifen enters tissues and binds to oestrogen receptors. In breast tissue, the tamoxifen–receptor complex reduces the ability of oestrogen to activate genes involved in tumour-cell growth. The drug does not remove oestrogen from the bloodstream. Its effect depends on the tissue and the receptor environment. This tissue-specific activity explains why tamoxifen’s effects vary across organs. [1]

Pharmacological Profile of Tamoxifen

Tamoxifen has a high affinity for oestrogen receptors. After binding, it changes receptor activity and alters the expression of oestrogen-responsive genes. This is why tamoxifen can block oestrogenic stimulation in breast tissue while producing partial oestrogen-like effects in some other tissues.

The drug is metabolised in the liver. Enzymes including CYP2D6 and CYP3A4 contribute to the formation of active metabolites, especially endoxifen. Medicines that inhibit CYP2D6 may reduce endoxifen exposure and can affect tamoxifen’s clinical activity.

Tell the prescribing team about antidepressants, especially paroxetine, fluoxetine, or other medicines that may inhibit CYP2D6. The interaction can affect tamoxifen metabolism rather than simply increasing ordinary side effects.

A practical detail is easy to miss: tamoxifen is not a general testosterone or oestrogen-balancing tablet. Its medical role is receptor-directed treatment, mainly within an oncology protocol.

Common mistakes

Several avoidable patterns can reduce the benefit of treatment:

  • Taking an extra tablet after an uncertain dose.
  • Stopping treatment when hot flushes improve, without a replacement plan.
  • Treating new vaginal bleeding as an ordinary menopausal symptom.
  • Forgetting to mention antidepressants or anticoagulants.
  • Assuming herbal products are automatically compatible with cancer treatment.
  • Leaving tablets in a humid bathroom or a hot vehicle.
  • Failing to tell the oncology team about planned surgery or long-distance immobility.
  • Using leftover hormones or hormone-containing products without approval.

One frequent misunderstanding concerns timing. Tamoxifen does not need to be taken immediately before a meal or at a special hour for an instant effect. The useful target is a regular daily schedule that fits the prescribed plan.

Comparison

Tamoxifen is one endocrine approach. Other options work through different hormonal pathways and may be selected according to menopausal status, tumour biology, previous treatment, recurrence risk, and tolerability.

Treatment approach Main mechanism
Tamoxifen Blocks oestrogen receptors in breast tissue while acting as a partial oestrogen agonist in selected tissues.
Aromatase inhibition Reduces the conversion of androgens into oestrogen, mainly used after menopause or with ovarian suppression in selected patients.
Ovarian suppression Reduces ovarian oestrogen production through medical or surgical means and may be combined with another endocrine treatment.

Tamoxifen may be preferred when receptor blockade is clinically appropriate, including in pre-menopausal patients who still produce ovarian oestrogen. Aromatase inhibition can be favoured after menopause in some treatment plans, though joint pain, bone loss, and cardiovascular considerations may influence selection.

These options are not interchangeable by tablet strength or symptom profile. A change from tamoxifen to another endocrine approach needs a defined oncology reason, since the mechanism, monitoring, and expected adverse effects differ.

What doctors say

In oncology practice, tamoxifen is judged by its effect on recurrence risk and treatment adherence, not by whether it produces noticeable daily sensations. A patient can receive benefit without feeling a change. The absence of side effects does not mean the medicine is inactive.

Clinicians also look for treatable causes behind poor adherence. Night sweats, low mood, sexual symptoms, and vaginal problems can make a patient skip doses long before they mention the problem. A direct conversation may lead to symptom treatment, a medicine review, or a planned endocrine change.

The trade-off is clear. Tamoxifen can provide an important oestrogen-blocking strategy, yet it can cause vasomotor symptoms and carries specific clotting and uterine risks. The right decision depends on the cancer subtype, menopausal status, medical history, and the available endocrine options.

What customers often ask

Can Nolvadex be used during pregnancy or breastfeeding?

Tamoxifen should not be used during pregnancy, and breastfeeding is generally avoided during treatment because of potential infant exposure and effects on milk production. The FDA prescribing information reviewed in 2024 identifies pregnancy-related harm as a specific concern with tamoxifen. A person who becomes pregnant while taking Nolvadex should contact the prescribing oncology team promptly for an individual plan.

What should be discussed with a doctor before starting Nolvadex?

The prescribing team should review previous clots, unexplained vaginal bleeding, liver disease, planned surgery, immobility, and every medicine or supplement being used. The TGA product information referenced in 2025 also makes medicine interactions and treatment monitoring relevant to the initial review. Antidepressants, anticoagulants, hormonal products, and enzyme-inducing medicines deserve specific attention because they can alter risk or tamoxifen metabolism.

Which condition rules out Nolvadex?

Pregnancy is a clear reason not to start tamoxifen. The 2024 FDA label identifies fetal harm as a major safety concern, so pregnancy must be excluded and contraception requirements discussed when clinically appropriate. A previous blood clot does not automatically have the same meaning in every treatment plan, but it requires a careful risk assessment before treatment.

What should be done after a missed Nolvadex dose?

If the missed tablet is remembered well before the next scheduled dose, the patient should follow the individual missed-dose instruction provided by the oncology team. If the next dose is close, the missed dose is generally skipped rather than doubled. NHS medicine guidance reviewed in 2025 uses this principle for tamoxifen safety, since taking extra tablets can increase adverse effects without restoring the treatment schedule.

How does tamoxifen differ from an aromatase inhibitor?

Tamoxifen blocks oestrogen receptors, while an aromatase inhibitor lowers the body’s production of oestrogen from androgen precursors. The European Medicines Agency’s endocrine-treatment information reviewed in 2024 reflects the importance of menopausal status when selecting between these approaches. Joint symptoms and bone effects may be more prominent with aromatase inhibition, while tamoxifen has distinctive clotting and uterine risks.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Arimidex

Active ingredient: Anastrozole
1mg
From $ 345.32
pills
4.3 (4)

Nolvadex Current

Active ingredient: Tamoxifen
10mg 20mg
From $ 158.42
pills
4.2 (3)

How the medicines for Breast Cancer compare

Sources

  1. U.S. Food and Drug Administration (2024). Nolvadex (tamoxifen citrate) Prescribing Information
  2. Therapeutic Goods Administration (2025). Tamoxifen: Australian Product Information
  3. National Institute for Health and Care Excellence (2024). Early and Advanced Breast Cancer: Diagnosis and Management

How Buyers Rate Nolvadex

Based on 3 reviews

Thomas, 61 Verified
Rating: 5 out of 5

I took Nolvadex after breast cancer treatment. The first month brought night sweats and interrupted sleep, but keeping the bedroom cooler made the evenings manageable. My oncology appointment helped me stay with the plan rather than stopping after the first difficult weeks.

The first month 3 Nov 2026
Lee, 28 Verified
Rating: 4 out of 5

I was prescribed tamoxifen as part of a specialist treatment plan. I noticed nausea during the first several days and started taking the tablet with breakfast, which suited me better. Mood changes were more difficult than the stomach symptoms, so I reported them instead of assuming they would disappear.

The first several days 5 Oct 2026
Harry C., 44 Verified
Rating: 3.5 out of 5

I had been taking the tablet regularly for several months when I developed calf swelling after a period of limited movement. The symptom needed urgent assessment. It was a reminder that clot-related symptoms should not be treated as an ordinary side effect.

Several months 20 Oct 2026
Get our free app Shop faster and track your orders 3.8 · 491 reviews Install